Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer

Laura W. Goff, Nilo Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka Vaishampayan, Howard Hochster, Roisin Connolly, Amy Weise, Patricia M. LoRusso, Safia N. Salaria, Wael El-Rifai, Jordan D. Berlin

Research output: Contribution to journalArticle

Abstract

Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURKA causes mitotic delays, severe chromosome congression, and activation of p53/p73 leading to cell death. Our preclinical data showed cooperative activity with the AURKA inhibitor alisertib and platinum agents in cell lines and xenografts, and suggested an optimal treatment window. Therefore, this study was designed to determine the maximum-tolerated dose (MTD) of alisertib in combination with modified FOLFOX (mFOLFOX), as this is a standard platinum-based therapy for gastrointestinal cancers. Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1–3), with leucovorin (400 mg/m2) and oxaliplatin (85 mg/m2) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m2) infusion on Days 2–4 in 14-day cycles. Fourteen patients with advanced gastrointestinal cancers were enrolled and two doses explored; two patients were not evaluable for dose-limiting toxicity (DLT) and replaced. Two patients experienced DLTs at 20 mg of alisertib (Grade 3 fatigue (n = 2); Grade 3 nausea, vomiting, dehydration with hospitalization (n = 1)). MTD was 10 mg alisertib with 85 mg/m2 oxaliplatin and 2400 mg/m2 5-FU. Most frequent toxicities were nausea (57%), diarrhea, fatigue, neuropathy, and vomiting (43%), and anorexia and anemia (36%); most were Grade 1–2. One patient with colorectal cancer had a partial response of 12 evaluable patients, and four patients had stable disease. Alisertib in combination with mFOLFOX did not demonstrate unexpected side effects, but the regimen was only tolerable at the lowest dose investigated.

Original languageEnglish (US)
JournalInvestigational New Drugs
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Aurora Kinases
Gastrointestinal Neoplasms
oxaliplatin
Aurora Kinase A
Maximum Tolerated Dose
Platinum
Fluorouracil
Nausea
Vomiting
Fatigue
Chromosomal Instability
Leucovorin
Anorexia
Dehydration
Heterografts
MLN 8237
Anemia
Colorectal Neoplasms
Diarrhea
Hospitalization

Keywords

  • Alisertib
  • Aurora kinase a inhibition
  • Gastrointestinal cancers
  • Modified FOLFOX

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Goff, L. W., Azad, N., Stein, S., Whisenant, J. G., Koyama, T., Vaishampayan, U., ... Berlin, J. D. (Accepted/In press). Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0663-0

Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. / Goff, Laura W.; Azad, Nilo; Stein, Stacey; Whisenant, Jennifer G.; Koyama, Tatsuki; Vaishampayan, Ulka; Hochster, Howard; Connolly, Roisin; Weise, Amy; LoRusso, Patricia M.; Salaria, Safia N.; El-Rifai, Wael; Berlin, Jordan D.

In: Investigational New Drugs, 01.01.2018.

Research output: Contribution to journalArticle

Goff, LW, Azad, N, Stein, S, Whisenant, JG, Koyama, T, Vaishampayan, U, Hochster, H, Connolly, R, Weise, A, LoRusso, PM, Salaria, SN, El-Rifai, W & Berlin, JD 2018, 'Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer', Investigational New Drugs. https://doi.org/10.1007/s10637-018-0663-0
Goff, Laura W. ; Azad, Nilo ; Stein, Stacey ; Whisenant, Jennifer G. ; Koyama, Tatsuki ; Vaishampayan, Ulka ; Hochster, Howard ; Connolly, Roisin ; Weise, Amy ; LoRusso, Patricia M. ; Salaria, Safia N. ; El-Rifai, Wael ; Berlin, Jordan D. / Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. In: Investigational New Drugs. 2018.
@article{623e09a964874ff5a8882a575a636427,
title = "Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer",
abstract = "Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURKA causes mitotic delays, severe chromosome congression, and activation of p53/p73 leading to cell death. Our preclinical data showed cooperative activity with the AURKA inhibitor alisertib and platinum agents in cell lines and xenografts, and suggested an optimal treatment window. Therefore, this study was designed to determine the maximum-tolerated dose (MTD) of alisertib in combination with modified FOLFOX (mFOLFOX), as this is a standard platinum-based therapy for gastrointestinal cancers. Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1–3), with leucovorin (400 mg/m2) and oxaliplatin (85 mg/m2) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m2) infusion on Days 2–4 in 14-day cycles. Fourteen patients with advanced gastrointestinal cancers were enrolled and two doses explored; two patients were not evaluable for dose-limiting toxicity (DLT) and replaced. Two patients experienced DLTs at 20 mg of alisertib (Grade 3 fatigue (n = 2); Grade 3 nausea, vomiting, dehydration with hospitalization (n = 1)). MTD was 10 mg alisertib with 85 mg/m2 oxaliplatin and 2400 mg/m2 5-FU. Most frequent toxicities were nausea (57{\%}), diarrhea, fatigue, neuropathy, and vomiting (43{\%}), and anorexia and anemia (36{\%}); most were Grade 1–2. One patient with colorectal cancer had a partial response of 12 evaluable patients, and four patients had stable disease. Alisertib in combination with mFOLFOX did not demonstrate unexpected side effects, but the regimen was only tolerable at the lowest dose investigated.",
keywords = "Alisertib, Aurora kinase a inhibition, Gastrointestinal cancers, Modified FOLFOX",
author = "Goff, {Laura W.} and Nilo Azad and Stacey Stein and Whisenant, {Jennifer G.} and Tatsuki Koyama and Ulka Vaishampayan and Howard Hochster and Roisin Connolly and Amy Weise and LoRusso, {Patricia M.} and Salaria, {Safia N.} and Wael El-Rifai and Berlin, {Jordan D.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10637-018-0663-0",
language = "English (US)",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer

AU - Goff, Laura W.

AU - Azad, Nilo

AU - Stein, Stacey

AU - Whisenant, Jennifer G.

AU - Koyama, Tatsuki

AU - Vaishampayan, Ulka

AU - Hochster, Howard

AU - Connolly, Roisin

AU - Weise, Amy

AU - LoRusso, Patricia M.

AU - Salaria, Safia N.

AU - El-Rifai, Wael

AU - Berlin, Jordan D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURKA causes mitotic delays, severe chromosome congression, and activation of p53/p73 leading to cell death. Our preclinical data showed cooperative activity with the AURKA inhibitor alisertib and platinum agents in cell lines and xenografts, and suggested an optimal treatment window. Therefore, this study was designed to determine the maximum-tolerated dose (MTD) of alisertib in combination with modified FOLFOX (mFOLFOX), as this is a standard platinum-based therapy for gastrointestinal cancers. Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1–3), with leucovorin (400 mg/m2) and oxaliplatin (85 mg/m2) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m2) infusion on Days 2–4 in 14-day cycles. Fourteen patients with advanced gastrointestinal cancers were enrolled and two doses explored; two patients were not evaluable for dose-limiting toxicity (DLT) and replaced. Two patients experienced DLTs at 20 mg of alisertib (Grade 3 fatigue (n = 2); Grade 3 nausea, vomiting, dehydration with hospitalization (n = 1)). MTD was 10 mg alisertib with 85 mg/m2 oxaliplatin and 2400 mg/m2 5-FU. Most frequent toxicities were nausea (57%), diarrhea, fatigue, neuropathy, and vomiting (43%), and anorexia and anemia (36%); most were Grade 1–2. One patient with colorectal cancer had a partial response of 12 evaluable patients, and four patients had stable disease. Alisertib in combination with mFOLFOX did not demonstrate unexpected side effects, but the regimen was only tolerable at the lowest dose investigated.

AB - Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURKA causes mitotic delays, severe chromosome congression, and activation of p53/p73 leading to cell death. Our preclinical data showed cooperative activity with the AURKA inhibitor alisertib and platinum agents in cell lines and xenografts, and suggested an optimal treatment window. Therefore, this study was designed to determine the maximum-tolerated dose (MTD) of alisertib in combination with modified FOLFOX (mFOLFOX), as this is a standard platinum-based therapy for gastrointestinal cancers. Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1–3), with leucovorin (400 mg/m2) and oxaliplatin (85 mg/m2) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m2) infusion on Days 2–4 in 14-day cycles. Fourteen patients with advanced gastrointestinal cancers were enrolled and two doses explored; two patients were not evaluable for dose-limiting toxicity (DLT) and replaced. Two patients experienced DLTs at 20 mg of alisertib (Grade 3 fatigue (n = 2); Grade 3 nausea, vomiting, dehydration with hospitalization (n = 1)). MTD was 10 mg alisertib with 85 mg/m2 oxaliplatin and 2400 mg/m2 5-FU. Most frequent toxicities were nausea (57%), diarrhea, fatigue, neuropathy, and vomiting (43%), and anorexia and anemia (36%); most were Grade 1–2. One patient with colorectal cancer had a partial response of 12 evaluable patients, and four patients had stable disease. Alisertib in combination with mFOLFOX did not demonstrate unexpected side effects, but the regimen was only tolerable at the lowest dose investigated.

KW - Alisertib

KW - Aurora kinase a inhibition

KW - Gastrointestinal cancers

KW - Modified FOLFOX

UR - http://www.scopus.com/inward/record.url?scp=85053459419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053459419&partnerID=8YFLogxK

U2 - 10.1007/s10637-018-0663-0

DO - 10.1007/s10637-018-0663-0

M3 - Article

C2 - 30191522

AN - SCOPUS:85053459419

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -